pubmed-article:11485630 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0001483 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0040669 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0010674 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0014609 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0458827 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C0013682 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C1112870 | lld:lifeskim |
pubmed-article:11485630 | lifeskim:mentions | umls-concept:C1522010 | lld:lifeskim |
pubmed-article:11485630 | pubmed:issue | 11 | lld:pubmed |
pubmed-article:11485630 | pubmed:dateCreated | 2001-8-3 | lld:pubmed |
pubmed-article:11485630 | pubmed:abstractText | A phase I clinical trial was conducted in which recombinant adenovirus containing the cystic fibrosis trans-membrane regulator (CFTR) (Ad2/CFTR) was administered by bronchoscopic instillation or aerosolization to the lungs of cystic fibrosis (CF) patients. In this paper, we evaluate the efficiency of Ad2/CFTR-mediated transduction of bronchial airway cells. The ability of an Ad2/CFTR vector to transduce airway cells was first evaluated in patients to whom the vector was administered by bronchoscopic instillation. Cells at the administration site were collected 2 days after treatment by bronchoscopic brushing. Ad2-specific CFTR DNA was detected in four of five individuals by PCR, and Ad2-specific CFTR RNA was detected in three of five individuals by RT-PCR. Ad2/CFTR-mediated transduction of airway epithelial cells was then determined in CF individuals receiving this vector by aerosol inhalation. Ad2-specific CFTR DNA was detected in 13 of 13 individuals 2 days after aerosolization, and in 3 of 5 individuals 7 days after aerosolization. Ad2-specific RNA was detected in 4 of 13 individuals on day 2, but was not detected in the 5 individuals tested on day 7. The percentage of airway epithelial cells containing nuclear-localized vector DNA was < or =2.4% as determined by fluorescence in situ hybridization (FISH). However, in some cases, a high percentage of nonepithelial mononuclear cells or squamous metaplastic epithelial cells was infected with the adenoviral vector. In conclusion, aerosol administration is a feasible means to distribute adenoviral vectors throughout the conducting airways, but improvements in adenovirus-mediated transduction of airway epithelial cells are necessary before gene therapy for CF will be effective. | lld:pubmed |
pubmed-article:11485630 | pubmed:language | eng | lld:pubmed |
pubmed-article:11485630 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11485630 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11485630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11485630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11485630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11485630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11485630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11485630 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11485630 | pubmed:month | Jul | lld:pubmed |
pubmed-article:11485630 | pubmed:issn | 1043-0342 | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:SmithA EAE | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:MorrisJ EJE | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:PavelkaKK | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:WadsworthS... | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:DorkinHH | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:JosephP MPM | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:O'SullivanB... | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:PerriconeM... | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:BalfourRR | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:MeekerD PDP | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:LapeyAA | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:St GeorgeJ... | lld:pubmed |
pubmed-article:11485630 | pubmed:author | pubmed-author:PlogM SMS | lld:pubmed |
pubmed-article:11485630 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11485630 | pubmed:day | 20 | lld:pubmed |
pubmed-article:11485630 | pubmed:volume | 12 | lld:pubmed |
pubmed-article:11485630 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11485630 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11485630 | pubmed:pagination | 1383-94 | lld:pubmed |
pubmed-article:11485630 | pubmed:dateRevised | 2006-4-21 | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:meshHeading | pubmed-meshheading:11485630... | lld:pubmed |
pubmed-article:11485630 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11485630 | pubmed:articleTitle | Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. | lld:pubmed |
pubmed-article:11485630 | pubmed:affiliation | Genzyme Corporation, Framingham, MA 01701, USA. michael. perricone@genyme.com | lld:pubmed |
pubmed-article:11485630 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11485630 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:11485630 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:11485630 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11485630 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11485630 | lld:pubmed |